Oncology Today with Dr Neil Love

Featuring perspectives from Prof Yohann Loriot, including the following topics:
Case: A man in his early 80s with metastatic urothelial bladder cancer (mUBC) receives enfortumab vedotin (EV)/pembrolizumab but experiences immune-related adverse events requiring steroids and then develops neuropathy due to EV — Nazli Dizman, MD (0:00)
Case: A man in his early 70s with diabetes who received adjuvant nivolumab for FGFR3-mutant metastatic urothelial cancer receives first-line EV monotherapy and experiences hyperglycemia and cancer progression, then receives erdafitinib and experiences elevated phosphase, Grade 2 diarrhea and stomatitis and eventual disease progression — Jacqueline T Brown, MD (7:00)
Case: A man in his late 80s with mUBC receives first-line EV/pembrolizumab and develops pneumonitis — Fern Anari, MD (17:40)

CME information and select publications

Featuring perspectives from Ms Blanca Ledezma, Dr Marissa Marti-Smith, Dr Heather McArthur and Dr Ruth M O'Regan, moderated by Dr McArthur, including the following topics:
Introduction (0:00)
Current Clinical Role of Oral Selective Estrogen Receptor Degraders (SERDs) in HR-Positive Metastatic Breast Cancer (3:37)
Practical Considerations with Oral SERDs (15:43)
Potential Role of Combination Approaches with Oral SERDs (26:33)
Gastrointestinal Adverse Events Documented with Oral SERDs (38:19)
Potential Role of Early Therapeutic Switching After Detection of an Emergent ESR1 Mutation (46:54)
Other Class-Effect Toxicities Associated with Oral SERDs (1:00:56)
Emerging Utility of Adjuvant Oral SERDs (1:10:20)
Unique Toxicities Associated with 1 or More Oral SERDs (1:19:22)

CME information and select publications

Featuring perspectives from Prof Yohann Loriot, including the following topics:
Case: A man in his early 80s with Parkinson disease and a history of renal transplant presents with metastatic urothelial bladder cancer (UBC) and receives first-line enfortumab vedotin (EV) with a good response but develops neuropathy and skin toxicity — Jacqueline T Brown, MD (0:00)
Case: A man in his early 90s with excellent PS and locally advanced UBC receives EV and pembrolizumab as palliative treatment, develops neuropathy, discontinues the EV and continues pembrolizumab with no toxicity — Catherine Fahey, MD, PhD (12:01)
Case: A woman in her late 50s with metastatic UBC receives EV with pembrolizumab on a clinical trial and experiences a response but develops diarrhea and pruritus — Fern Anari, MD (21:43)

CME information and select publications

Featuring perspectives from Dr Amrita Krishnan and Dr Robert Z Orlowski, including the following topics:
Introduction (00:00)
Up-Front Progression-Free Survival for Standard-Risk Disease — 2006, 2016 (1:47)
Current and Emerging Therapeutic Approaches — Dr Orlowski (10:34)
Chimeric Antigen Receptor T-Cell Therapy, Bispecific Antibodies and Antibody-Drug Conjugates — Dr Krishnan (27:15)
ASCO and EHA 2026 (46:37)

CME information and select publications

Featuring perspectives from Dr Terence Friedlander, Dr Matthew Galsky, Dr Shilpa Gupta and Prof Andrea Necchi, moderated by Dr Friedlander, including the following topics:
Case: A woman in her late 60s with T3N0 upper tract urothelial carcinoma that was resected has no evidence of disease on imaging, receives negative circulating tumor DNA results and elects observation instead of adjuvant treatment (0:00)
Case: A man in his late 70s with PD-L1-negative high-grade muscle-invasive bladder cancer who is ineligible for cisplatin because of poor renal function undergoes cystectomy (10:12)

CME information and select publications